<SEC-DOCUMENT>0001714899-21-000066.txt : 20210726
<SEC-HEADER>0001714899-21-000066.hdr.sgml : 20210726
<ACCEPTANCE-DATETIME>20210726082959
ACCESSION NUMBER:		0001714899-21-000066
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210725
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210726
DATE AS OF CHANGE:		20210726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		211112532

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8548

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20210725.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:8c6aa968-3f70-428d-b4b9-2acab5bc2a06,g:74f81abc-d11e-4793-9c94-771097bb9046,d:07e4f8568dc5477385027cad7d8ba126--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20210725</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl80L2ZyYWc6NmZkNzEwNGRmMzU5NGZiMThkOGZhMzNhMGUyOWQ5YjIvdGFibGU6YmM3YWFhZTVlNGM5NDNjNThiNjQyNzkyMWNlODM2MTcvdGFibGVyYW5nZTpiYzdhYWFlNWU0Yzk0M2M1OGI2NDI3OTIxY2U4MzYxN18yLTEtMS0xLTA_5acc48b8-2884-486b-9968-c96a21420638">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl80L2ZyYWc6NmZkNzEwNGRmMzU5NGZiMThkOGZhMzNhMGUyOWQ5YjIvdGFibGU6YmM3YWFhZTVlNGM5NDNjNThiNjQyNzkyMWNlODM2MTcvdGFibGVyYW5nZTpiYzdhYWFlNWU0Yzk0M2M1OGI2NDI3OTIxY2U4MzYxN18zLTEtMS0xLTA_ad1f0d96-c2b8-48bc-953e-f5fb9c3d968f">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20210725.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-25</xbrli:startDate><xbrli:endDate>2021-07-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i07e4f8568dc5477385027cad7d8ba126_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDE4_fd429370-bf0c-427e-a6e9-b2e9764f4ec2">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18yMzI_f545fb5f-baf0-4199-81af-0e017ec83dde">July 25, 2021</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDE5_639a7e9a-403a-40e1-86e5-954ec7ab5827">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6YTc4NGY5ZjlkOWJmNDdmMDhmZjAzMjNkMTc1NjdkMDgvdGFibGVyYW5nZTphNzg0ZjlmOWQ5YmY0N2YwOGZmMDMyM2QxNzU2N2QwOF8wLTAtMS0xLTA_36b6e605-dc23-4c0a-a36a-8c8041550067">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6YTc4NGY5ZjlkOWJmNDdmMDhmZjAzMjNkMTc1NjdkMDgvdGFibGVyYW5nZTphNzg0ZjlmOWQ5YmY0N2YwOGZmMDMyM2QxNzU2N2QwOF8wLTItMS0xLTA_9ab34082-1b1e-4d04-af5d-934c920d19a7">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6YTc4NGY5ZjlkOWJmNDdmMDhmZjAzMjNkMTc1NjdkMDgvdGFibGVyYW5nZTphNzg0ZjlmOWQ5YmY0N2YwOGZmMDMyM2QxNzU2N2QwOF8wLTQtMS0xLTA_b0562af1-5cc1-4efe-97ef-e53d10ece82e">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIz_a1338a5b-908e-4eeb-a909-e8fcde5eb2c9">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIw_7142b4dc-99a3-4588-b5e1-b0544216ed9c">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDI1_8b084f9c-742f-4c2c-8fa1-b20dea0d410b">California</ix:nonNumeric> <ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18zNzc_9d343123-2411-4e33-ac60-edf7edef127d">94080</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIx_e1a74c17-27c2-40ae-938b-0bafaa97ab5b">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIy_ac939379-f2a5-481b-83e8-2625feb8cb12">866-8548</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8wLTAtMS0xLTA_6814c650-ef18-40ca-8e2b-937d9705c627">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8xLTAtMS0xLTA_c6182e60-4ba3-4959-98cc-7e7c3bf60943">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8yLTAtMS0xLTA_87b19725-b978-4764-bb66-32653d2ed511">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8zLTAtMS0xLTA_b4bb0f37-73fd-47f9-8c3c-492c5b40d5a7">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6NTc3MzNjNTg5ZmY3NDcwODg4NzA0NmRjNGEyMzE4OTgvdGFibGVyYW5nZTo1NzczM2M1ODlmZjc0NzA4ODg3MDQ2ZGM0YTIzMTg5OF8wLTEtMS0xLTA_4ac01fac-3ede-45b3-8078-b2ed99b9478c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6ZWViODBhMWFiODFiNGQ2NWFmZWQwYzc3YmQ0ZTY3ZDcvdGFibGVyYW5nZTplZWI4MGExYWI4MWI0ZDY1YWZlZDBjNzdiZDRlNjdkN18xLTAtMS0xLTA_cace6d29-1aa1-4c3f-9f71-0073b23b46d9">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6ZWViODBhMWFiODFiNGQ2NWFmZWQwYzc3YmQ0ZTY3ZDcvdGFibGVyYW5nZTplZWI4MGExYWI4MWI0ZDY1YWZlZDBjNzdiZDRlNjdkN18xLTEtMS0xLTA_52c7c7c8-836a-4a59-8806-43526e3ef7ab">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6ZWViODBhMWFiODFiNGQ2NWFmZWQwYzc3YmQ0ZTY3ZDcvdGFibGVyYW5nZTplZWI4MGExYWI4MWI0ZDY1YWZlZDBjNzdiZDRlNjdkN18xLTItMS0xLTA_06d8b21f-f0c9-4e1c-8b6f-545883c0ded7">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07e4f8568dc5477385027cad7d8ba126_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01&#160;&#160;&#160;&#160;Other Events.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2021, the Company issued a press release announcing positive interim data from the Phase 1/2 study of ETV:IDS (DNL310) for the potential treatment of Hunter Syndrome that was presented at MPS 2021, the 16th Annual International Symposium of MPS and Related Diseases, which took place virtually on July 25, 2021.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished in this Item 8.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Exhibits</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex991pressrelease7262021.htm">Press </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex991pressrelease7262021.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex991pressrelease7262021.htm">elease dated July 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex991pressrelease7262021.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%;text-decoration:underline" href="ex991pressrelease7262021.htm">, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">104</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:83%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07e4f8568dc5477385027cad7d8ba126_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify;text-indent:37pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 26, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991pressrelease7262021.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3a998310606b48008a8ff559d075c18e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">99.1</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.211%"></td><td style="width:0.1%"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:0 1pt"><div><img alt="denali_txlogox01a.jpg" src="denali_txlogox01a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Denali Therapeutics Announces Positive Interim Data from Phase 1&#47;2 Study with ETV&#58;IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in urine and serum heparan sulfate after switching from standard-of-care idursulfase</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global Impression of Change scales data suggested clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilities</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Exploratory biomarker data demonstrated reductions in CSF lysosomal lipid biomarkers that are consistent with improved lysosomal function&#59; and high variability in exploratory biomarker Nf-L was observed pre- and post-treatment</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Safety profile with up to 43 weeks of dosing was consistent with standard of care enzyme replacement therapy with infusion-related reactions being the most frequently observed adverse events</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on these data, Denali is accelerating efforts to initiate a pivotal Phase 2&#47;3 study in 1H 2022</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Management will host a webinar for analysts and investors at 11&#58;30 a.m. Eastern Time today</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SOUTH SAN FRANCISCO, Calif., July 25, 2021 </font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Denali Therapeutics Inc. (NASDAQ&#58; DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced additional positive interim data from a Phase 1&#47;2 study evaluating ETV&#58;IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II). The interim results being presented today at MPS 2021, the 16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> International Symposium on MPS and Related Diseases, include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively, 6-month biomarker data from Cohort A and up to 3-month biomarker data from Cohort B. Denali Management will host a webinar today for analysts and investors beginning at approximately 11&#58;30 a.m. Eastern Time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The longer-term safety data and 6-month biomarker data on DNL310 from Cohort A continue to demonstrate durability of effect with CNS impact, improved peripheral activity after switching from standard of care, and a safety profile consistent with standard of care enzyme replacement therapy,&#8221; said Carole Ho, M.D., Denali&#8217;s Chief Medical Officer. &#8220;We are also encouraged by initial indications of improved clinical symptoms and function reported by investigators and parents in all five patients enrolled in Cohort A. In addition, this is the first time we are sharing data from Cohort B, which is designed to inform dose selection, and exploratory biomarker data demonstrate activity of DNL310 across all dose regimens. Based on these data, we are accelerating our efforts to initiate a pivotal Phase 2&#47;3 study of DNL310 in the first half of 2022 and to begin enrolling Cohort C in the Phase 1&#47;2 study to further investigate clinical endpoints.&#8221;    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This interim analysis of the Phase 1&#47;2 study included data on five patients enrolled in Cohort A and 12 patients enrolled in Cohort B. All patients have neuronopathic MPS II disease except for one patient with non-neuronopathic MPS II disease in Cohort B. The median age of patients is 6 years in both cohorts, with the youngest patients aged 5 and 2 in Cohorts A and B, respectively. All patients received weekly intravenous doses of DNL310 after switching from idursulfase enzyme replacement therapy on Day 1 of the study. Data being presented include safety data up to Weeks 43 and 25 from Cohorts A and B, respectively&#59; 6-month and up to 3-month biomarker data from Cohorts A and B, respectively&#59; and exploratory clinical Global Impression of Change data from Cohort A up to Week 24. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results across Cohorts A and B showed that, following the switch from idursulfase to DNL310, the levels of heparan sulfate in cerebrospinal fluid (CSF) normalized in all patients analyzed (n&#61;15), with rapid response observed in most patients (n&#61;12) by Week 7, which is consistent with crossing of the BBB by DNL310 and activity in tissues of the CNS. Rapid normalization of CSF heparan sulfate at low dose regimens suggest that BBB crossing with Denali&#8217;s Transport Vehicle (TV) was robust and efficient. Furthermore, the observed decline in urine and serum heparan sulfate was consistent with improved peripheral activity with DNL310.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exploratory clinical data suggest improved clinical symptoms and function for all five patients enrolled in Cohort A as reported by investigators and parents. Based on Global Impression of Change scales &#91;Clinician Global Impression of Change (CGI-C) and Parent Global Impression of Change (PGI-C)&#93;, which are standardized assessment scales used to measure change, the data showed clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilities. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exploratory lysosomal lipid data showed reductions, which are consistent with improved lysosomal function&#58; 10 of 15 patients across Cohorts A and B had normal GM3 ganglioside levels, including patients on low dose regimens and with shorter duration of treatment. In addition, reductions in levels of bis(monoacyl glycerol)-phosphate (BMP) and a potential reduction in levels of glucosylceramide (GlcCer) were observed in Cohort A at Week 24. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">High within patient variability in levels of neurofilament (Nf-L), an exploratory biomarker of neuronal structure, was observed pre- and post-treatment. Data from an ongoing observational natural history study conducted by Denali showed a marked increase in mean levels of serum Nf-L over a 4.5- to 6-month period in patients (n&#61;3) who subsequently enrolled in Cohort A of the Phase 1&#47;2 study. During the 6-month treatment period of the Phase 1&#47;2 study, mean levels of serum and CSF Nf-L in Cohort A (n&#61;5) showed a modest increase. Denali believes that the utility of Nf-L as a treatment response biomarker in MPS II will require further investigation. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile of DNL310 remained consistent with standard of care enzyme replacement therapy. DNL310 was generally well tolerated with the most common treatment-emergent adverse events being infusion-related reactions (IRRs). IRRs occurred in 12 of 17 (71%) patients&#58; the majority had mild (n&#61;5) or moderate (n&#61;6) IRRs, and 1 patient had severe IRRs. A total of 3 serious adverse events (SAEs) were reported&#58; 1 previously reported SAE for a patient enrolled in Cohort A based on a mild IRR, and 2 SAEs in a patient enrolled in Cohort B based on severe IRRs. The SAEs resolved, and both patients are continuing in the study. All other treatment-emergent adverse events were mild or moderate.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study continues without modification following recommendation by an independent data monitoring committee on July 9, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;DNL310 is our lead program enabled by our blood-brain barrier Transport Vehicle platform, and these data continue to validate the platform&#8217;s potential as we advance additional TV-enabled programs toward the clinic,&#8221; said Ryan Watts, Ph.D., Denali&#8217;s Chief Executive Officer. &#8220;Our DNL310 program exemplifies application of Denali&#8217;s core scientific principles to increase likelihood of success by targeting degenogenes, engineering therapeutics to cross the blood-brain barrier, and using biomarkers to inform development. We are encouraged by these interim data and we look forward to continued collaboration with the community to advance MPS II research and DNL310 as a potential treatment for affected individuals and their families.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Families interested in learning more about Denali&#8217;s efforts related to the discovery and development of therapeutics for the potential treatment of Hunter syndrome are invited to visit</font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EngageHunter.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Denali Hunter syndrome community engagement website.</font></div><div><font><br></font></div><div><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Webinar for Analysts and Investors</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali will host a webinar for analysts and investors to present the interim data from the Phase 1&#47;2 study of DNL310. The webinar will begin at approximately 11&#58;30 a.m. EDT &#47; 8&#58;30 a.m. PDT on Sunday, July 25, 2021, and will be available on Denali&#8217;s corporate website on the Events page under the Investor section and can be accessed by following this</font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An archived replay of the webinar will be available for at least 30 days following the event. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About DNL310 and Hunter Syndrome (MPS II)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hunter syndrome (MPS II) is a rare neurodegenerative lysosomal storage disease caused by mutations in the gene that encodes for the enzyme iduronate-2-sulfatase (IDS). The resultant reduction or loss of IDS enzyme activity leads to accumulation of glycosaminoglycans, which causes lysosomal dysfunction and neurodegeneration as well as progressive damage to multiple organs including bone, cartilage, heart and lung. Current standard of care enzyme replacement treatment does not address neuronopathic manifestations of the disease as it does not sufficiently cross the blood-brain barrier (BBB). DNL310 is an investigational fusion protein composed of IDS fused to Denali&#8217;s proprietary Enzyme Transport Vehicle (ETV), which is engineered to cross the BBB via receptor-mediated transcytosis into the brain. More information about the ongoing Phase 1&#47;2 study of DNL310 in patients with Hunter syndrome can be found on</font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ClinicalTrials.gov</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by following this</font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Denali&#8217;s TV Platform</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BBB is essential in maintaining the brain&#8217;s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for CNS diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali&#8217;s TV platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the BBB after intravenous administration. The TV technology is based on engineered Fc fragments that bind to specific natural transport receptors, such as transferrin receptor, which are expressed at the BBB and deliver TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered to the TV technology demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. ETV&#58;IDS (DNL310) is Denali&#8217;s lead TV-enabled program in Phase 1&#47;2 development for the potential treatment of Hunter syndrome (MPS II).</font></div><div><font><br></font></div><div><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EngageHunter.com</font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Website</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EngageHunter.com</font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Denali Hunter syndrome (MPS II) community engagement website &#8212; is an online destination for emerging information on Denali&#8217;s scientific advances in Hunter syndrome research and Denali&#8217;s clinical trials. Visitors who register on the Engage Hunter website will receive updates on Denali&#8217;s research and future Denali investigational studies.</font></div><div><font><br></font></div><div><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Denali Therapeutics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit</font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.denalitherapeutics.com</font><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#2d3644;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines and expectations related to DNL310, the DNL310 ongoing Phase 1&#47;2 study and expectations regarding enrollment in Cohort C, plans to accelerate efforts to initiate the planned Phase 2&#47;3 in the first half of 2022, plans regarding other planned future studies, expectations regarding Denali&#8217;s TV technology platform, the therapeutic potential of DNL310 and Denali&#8217;s TV platform, and statements made by Denali&#8217;s Chief Medical Officer and Chief Executive Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to&#58; Denali&#8217;s early stages of clinical drug development&#59; Denali&#8217;s and its partners&#8217; ability to complete the development and, if approved, commercialization of DNL310&#59; Denali&#8217;s and its partners&#8217; ability to enroll patients in its ongoing and future clinical trials&#59; Denali&#8217;s reliance on third parties for the manufacture and supply of its product candidates for clinical trials&#59; the potential for clinical trial results of DNL310 to differ from preclinical, preliminary or expected results, the risk that Denali will be able to continue dose escalation in the Phase 1&#47;2 study, whether DNL310 will cause any serious adverse events, whether DNL310 will impact downstream biomarkers of neurodegeneration, the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies&#59; and that DNL310 may not receive regulatory approval as a treatment of Hunter syndrome necessary to be commercialized. In light of these risks, uncertainties and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Information regarding additional risks and uncertainties may be found in Denali&#8217;s Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 26, 2021, and May 5, 2021, respectively, and Denali&#8217;s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali&#8217;s expectations, except as required by law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Relations Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laura Hansen, Ph.D.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(650) 452-2747</font></div><div><font style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">hansen&#64;dnli.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lizzie Hyland</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(646) 495-2706</font></div><div><font style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Lizzie.Hyland&#64;FGH.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morgan Warners</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202) 295-0124</font></div><div><font style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Morgan.Warners&#64;FGH.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20210725.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8c6aa968-3f70-428d-b4b9-2acab5bc2a06,g:74f81abc-d11e-4793-9c94-771097bb9046-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20210725" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20210725">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210725_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210725_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dnli-20210725_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8c6aa968-3f70-428d-b4b9-2acab5bc2a06,g:74f81abc-d11e-4793-9c94-771097bb9046-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_03115382-f848-4bc1-bdee-a747636e4e81_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ef46b118-3abe-419b-a8cf-12419156d81a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a2a777f4-f1da-4bc7-b485-3fa2945df89a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bc51068d-d787-44a9-884c-ba2ad28f939f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ac7c1f49-c5fd-46b4-be52-1f28b27a155b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_227c7097-176b-430d-813c-8a44aabe5246_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e370848a-16df-4ead-8844-25c341d7ff53_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_04840e14-279b-4d98-aa84-95c3038820ad_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_45d66fa6-e0ff-44a3-991f-18fb58edac25_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_20420960-fbea-45ea-b644-3e64b32a31ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_43fa7519-e59b-408e-ad03-e0fc81e875d3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_00ae04a8-9b06-46bb-8787-136ed0b10ce3_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0a6be893-c6c7-4d17-8ce6-5544e6d28004_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_10b2c791-5baf-4d54-8376-3330460458c7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f04aa6a8-3b5c-475c-b553-5a034c776a66_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bba90fcd-6385-441c-b75a-ab73e902b404_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3e6dd5a6-bd87-4e63-8dc5-689416b90566_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f6523fbb-aa51-4df7-a8c0-18290151b8c3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_57dc3866-93a9-48eb-8de4-c03b7421c0e4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_85051205-c333-490e-936d-656c4a515b1d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7b17b775-891d-431e-b9bf-f107fff55e99_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_074e5d61-1c3d-453a-b812-ee6e7063e76c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dnli-20210725_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:8c6aa968-3f70-428d-b4b9-2acab5bc2a06,g:74f81abc-d11e-4793-9c94-771097bb9046-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20210725.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5f7e641a-2b54-4929-86a8-0db0fdf7ef61" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_DocumentType_5f7e641a-2b54-4929-86a8-0db0fdf7ef61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1f7244d8-067c-47b7-87bd-b3563996a626" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_DocumentPeriodEndDate_1f7244d8-067c-47b7-87bd-b3563996a626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5edaf8df-35b8-4990-913c-0e18e27623b0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityRegistrantName_5edaf8df-35b8-4990-913c-0e18e27623b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e691a264-91ec-4c19-8a56-d553f0eca9ca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e691a264-91ec-4c19-8a56-d553f0eca9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9469b4f5-02b1-4e6d-aef9-08fdf0042fdb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityFileNumber_9469b4f5-02b1-4e6d-aef9-08fdf0042fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dbf0fae8-4458-4eb6-bf90-93e003c2026a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityTaxIdentificationNumber_dbf0fae8-4458-4eb6-bf90-93e003c2026a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6bf4d11b-115d-4007-b04a-1ba210361979" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityAddressAddressLine1_6bf4d11b-115d-4007-b04a-1ba210361979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7b15d330-f6d1-420e-86a5-859dd5635232" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityAddressCityOrTown_7b15d330-f6d1-420e-86a5-859dd5635232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_25845404-ed95-4896-bf5d-57527b3d1b5a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityAddressStateOrProvince_25845404-ed95-4896-bf5d-57527b3d1b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b5f3ee8c-664a-4c14-9a4d-beca0d30956f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityAddressPostalZipCode_b5f3ee8c-664a-4c14-9a4d-beca0d30956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b1479050-8708-48af-bb57-d3128954e99d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_CityAreaCode_b1479050-8708-48af-bb57-d3128954e99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9ebb91c2-4449-46e3-9cd7-88465a8b0b03" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_LocalPhoneNumber_9ebb91c2-4449-46e3-9cd7-88465a8b0b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_63c28009-0f77-4460-a15c-46e2c06222ad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_WrittenCommunications_63c28009-0f77-4460-a15c-46e2c06222ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0b83bff2-2238-4216-befa-362a20b4b047" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_SolicitingMaterial_0b83bff2-2238-4216-befa-362a20b4b047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_51864aa1-3e45-467b-937d-bc1d7e1c4bbc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_PreCommencementTenderOffer_51864aa1-3e45-467b-937d-bc1d7e1c4bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_748fda9b-8bc2-4aa9-94a6-4e805273f87d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_748fda9b-8bc2-4aa9-94a6-4e805273f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0b2aedc5-0f6d-4e17-9a5a-8e4116136906" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityEmergingGrowthCompany_0b2aedc5-0f6d-4e17-9a5a-8e4116136906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1c1b51eb-0e29-4beb-8a8d-cc2e1ccce17a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_Security12bTitle_1c1b51eb-0e29-4beb-8a8d-cc2e1ccce17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_01b39b39-d50c-4e12-ae89-35d760217893" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_TradingSymbol_01b39b39-d50c-4e12-ae89-35d760217893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8e50bc93-9ea8-4c23-85e2-38eb38a2e262" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_SecurityExchangeName_8e50bc93-9ea8-4c23-85e2-38eb38a2e262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_09394f2a-7de0-4748-83d1-ad5ba78db492" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_EntityCentralIndexKey_09394f2a-7de0-4748-83d1-ad5ba78db492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_31d867df-cfed-4cff-a15b-66a261a73ccb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b13e7341-c63a-47eb-98e8-95a377677a7c" xlink:to="loc_dei_AmendmentFlag_31d867df-cfed-4cff-a15b-66a261a73ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>denali_txlogox01a.jpg
<TEXT>
begin 644 denali_txlogox01a.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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MQ #7  $  @,! 0$! 0          "0H%!P@&! ,! @$!  (# 0$! 0
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M4HT]:^[KTD@D(1:X\=<==(X^V5+ERVRVF9GH]D-&CHY
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M%HUK.L,R,,@                #G#>OFJV?V+2N'E%XNVRC@2IK#<:2Q9Y
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M,UTU:UF2&VWRB27EGHAE0BY-O>G3'35-Q[G'DZ.%OI=EC@D
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ME'"4B%*)"E192$DW(01]"7$.-MUN3';';2>"VQ9:Y:\U>/MCJ;M'-T
M       '^5K0VA;CBTMMMI4M:UJ)*$(21J4M:E&24I2DM3,^@B 1#<U?/S*5
M(L=O-AK,F(S77P;W<F*9G(D.D:V9$+#%FDDL,-:&1VA<2W%'K%X$I0^Y-P[;
M]63^'XJ_/NOT8OX_A^*)N3)D3)#\N7(>E2I+KC\F3)=6_(D/NJ-;KS[SJE..
MNN+,S4I1F9F>IB8@\>F>+\08                     $_O=V_9MK/C?E?J
MJ.*[<^;W+;:>3';+N@1TD          'R3Y\&J@S+.SF1J^NKXS\V?/FOM18
M<*'%:4])E2I+RD,L1V&4&I:U&24I(S,] B)F=(XDS$1K/!"WS2<^UUETBQP7
M9*PET6(H-R)8YO'Z^#?Y(6AH>13&M+,NAIU:F1.:(FOEH>K*3-"I^';Q7\V3
MQ=2MS[J;?EQ]%>M&4I2EJ4M:C4I1FI2E&:E*4H]34HSU,S,SZ3$I"?P
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M2ETS,]3*P(B+A1T0=U32T7CA*RV>36LXYXQP2A"(F@
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M+3FC';PTF7,__P#K7_\ Z*_B6.O_ */_ (?N</\ U_\ Q_>YU'1Q
M                 &T-G]W,NV4SBKSC$)BFI4-Q+5G6...)KL@IUN(7-I;5
MI!Z.Q):4%HK3C9=)+K9DXA)EK>E<E>6SICR6QVYJK*6U6YF-[OX'09_BKYN5
MEW&XW(KJD',JK%A1LV-18(09DW,KY25(5_JK3PN(U0M*CJKTFEIK/%<4O&2L
M7KPEL,:MP           $1?/YS4/(>L=A=OK$VD)03&Y5W"=,EK4LD.>\R'(
M;,C0A*-#LS0?IN+LJC(BDMG-VV'_ -2W=^*!NL__ *5._P##\41PF*\
M                  !/[W=OV;:SXWY7ZJCBNW/F]RVVGDQVR[H$=)
M    !"7SY\TS^9W=ALK@EB:<.Q^8<?-+**LN')\A@R"-=2TZ1<:J6@E,Z*,E
M$F3+2H]#0TTM<_;X>6/>6\4\%;NL_-/NZ^&./THSA*0@
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M6=;.CJXX\VOGQVY4.6PO0N)F1'=2M)^BDR%3,3$Z3Q743$QK'!]XPR
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MZ :26?&[XFL">C*-/I6F%1D]&I:U^ZIRWYXX3]JTV>3FIR3QK]B141DL
M              $:7>>_1+M_YQ4?-J]$K:>.>Q"WOEQVH1Q/5H   #O[NV_M
M#3?-UDONGCHC[KRN]+V?G=TIYQ7+0                              $
M1G>H?L)_>?\ P\$W9_J[OO0-]^GO^Y$:)BO    2B=UY^?NZ/Q0I_=E0B;OP
MQVIVR\5NQ-"(*Q         %7[?'9/+]C<XM,5R6NF)KTS)2L:R!3"_%N1TQ
M.<4.="EI049R1V9:.TLI/CCO&:%$6A:VV/)7)7FA2Y<5L5N6W#V--C=R
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MOOT]_P!R(T3%>    E$[KS\_=T?BA3^[*A$W?ACM3MEXK=B:$05B
M /CG5\"TCKAV4&'8Q'/]I%G1F9<=?0:?3L2$.-*]*HRZ2\!A$S' F(GB\YY/
ML"^!&(?)JF]9#;FMURUY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;
MUD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'
MD^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;
MUD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'
MD^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;
MUD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4'D^P+X$8A\FJ;UD'-;KDY:]4.
M;-].2[:/=REGNTF/U& YPEEUVJR7'*]BLBOS>'B0UD55 ;9B6D20LB)QW@*6
M@NE#G0:%=<>>])Z9UJXY=MCR1T1I;KA7\RS%[O"<EO<1R2&JOO<<M)E1:1%&
M2R:EPGE,N&TZGTC\=WAXVG$ZH<;4E23-)D8L8F+1S1PE56K-;36W&'GQEJ
M  G_ .[OR-V]Y;ZVO=<ZSWI9;E&.-ZF9J0TZ]%R9#:C,S,^ LC]+X-$:$700
MKMS&F77KA;;2=<.G5,_B[F$=)         %8[F;R1W+.8+=^X=<-XO?W>U$9
MT^+T\#')2L<K3+C,U$GQ?5-:$>FA>@7@%MBC3'6/H4N>W-EM/T_9T-%C=R
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MCI4F/;5T&R82K7B2S.C-2FDJU2D^(D.EKT%_H%/,:3HO8G6-61&&0
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M0M[Y<=J$<3U:    [^[MO[0TWS=9+[IXZ(^Z\KO2]GYW=*><5RT
M                     !$9WJ'["?WG_P /!-V?ZN[[T#??I[_N1&B8KP
M $HG=>?G[NC\4*?W94(F[\,=J=LO%;L30B"L0
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M/&M1-(326C;$E:S+B)A#J4Z<9CEGI[S',>V.F'?;Y/=Y(F?#/1*R(*M<
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M\95!MDXZKI<E,O\ AT%9GIR9.CA/2M]MD]YBC7Q1T.NQQ2
M  $:7>>_1+M_YQ4?-J]$K:>.>Q"WOEQVH1Q/5H   #O[NV_M#3?-UDONGCHC
M[KRN]+V?G=TIYQ7+0                              $1G>H?L)_>?\
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M]1/#,<6+<)[%3$7"A     %L['O8"C]J*WU$R*>>*^KPCL9<89
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MIXY[$+>^7':A'$]6@   ._N[;^T--\W62^Z>.B/NO*[TO9^=W2GG%<M
M                          1&=ZA^PG]Y_P##P3=G^KN^] WWZ>_[D1HF
M*\   !*)W7GY^[H_%"G]V5")N_#':G;+Q6[$T(@K$
M            ! QWDGVAH7FZQKW3R(6.U\KO5>\\[NAP")"(    FX[L+Z)=
MP/.*OYM40@;OQQV++9>7/:DM$5-         %4C<#\_,V^-V2>[,T7%?#'8H
M[^.>V7D1EH    M$<O\ ] VR7FBVV^9M**G)YEO]4_:N\7E5_P!,?8VZ-'0
M                            8C(?8"\]J++U$\,QQ8MPGL5,1<*$
M 6SL>]@*/VHK?43(IYXKZO".QEQAD               !4PO_9VZ]MK+U8\+
MF."AMQGM8D&    %I_9[Z(]K?-SA'S9K!47\<]LKS'Y=>R&QAJW
M       1B\^^Z/72J#:6L?/@B=3E&4&VL]#DO-NLT58Z25%TLQUN2G$*(R/K
M6%%TI'Q#_E?ZY]YGVG]O]C;\N/3<[K2?U3$Q@Q3V5FV6T3K$\V*8Z8?9W^+G
MHKW>#=>N][7\V37;;;6/TQ,3FR1VVBN.LQI,<N6)Z)1M#XP?8(     F^Y/L
M'F81LC1%8M+CS\KG3<RD1G")*V6;9J)%J^(M",E/TM=&=,C],DW.$_ /3O\
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M(-!?>F*O-3W>28]GL7.#)[S'%O;PET@.3L              "-+O/?HEV_\
M.*CYM7HE;3QSV(6]\N.U".)ZM    =_=VW]H:;YNLE]T\=$?=>5WI>S\[NE/
M.*Y:                               B,[U#]A/[S_X>";L_U=WWH&^_
M3W_<B-$Q7@   )1.Z\_/W='XH4_NRH1-WX8[4[9>*W8FA$%8@
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M."AMQGM8D&    %I_9[Z(]K?-SA'S9K!47\<]LKS'Y=>R&QAJW
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M$<3U:    [^[MO[0TWS=9+[IXZ(^Z\KO2]GYW=*><5RT
M              !$9WJ'["?WG_P\$W9_J[OO0-]^GO\ N1&B8KP   $HG=>?
MG[NC\4*?W94(F[\,=J=LO%;L30B"L0
M $#'>2?:&A>;K&O=/(A8[7RN]5[SSNZ' (D(@   ";CNPOHEW \XJ_FU1"!N
M_''8LMEY<]J2T14T         52-P/S\S;XW9)[LS1<5\,=BCOXY[9>1&6@
M                      "S'RIS9<_ESV>D39#LI\L*K8W7/+-;G40C=A1&
MC4?2:6(L=#:?N)20JLWFV[5U@Z<->QT$.;J         ,1D/L!>>U%EZB>&8
MXL6X3V*F(N%"     +9V/>P%'[45OJ)D4\\5]7A'8RXPR
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MM/'/8A;WRX[4(XGJT   !W]W;?VAIOFZR7W3QT1]UY7>E[/SNZ4\XKEH
M                          "(SO4/V$_O/_AX)NS_ %=WWH&^_3W_ '(C
M1,5X   "43NO/S]W1^*%/[LJ$3=^&.U.V7BMV)H1!6(
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M   #O[NV_M#3?-UDONGCHC[KRN]+V?G=TIYQ7+0
M         $1G>H?L)_>?_#P3=G^KN^] WWZ>_P"Y$:)BO    2B=UY^?NZ/Q
M0I_=E0B;OPQVIVR\5NQ-"(*Q                                0,=Y
M)]H:%YNL:]T\B%CM?*[U7O/.[H< B0B    )N.["^B7<#SBK^;5$(&[\<=BR
MV7ESVI+1%30        !5(W _/S-OC=DGNS-%Q7PQV*._CGMEY$9:
M                 ++7*1]FW9_XHQ_5<L5>;S;=JZP>37L=%CDZ@
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M>.I<.ZK#XE*5_P"GVL=YHC,SXDH)1:D9&*B]9I::S[%WCO&2D7CVMDC5N
M         C2[SWZ)=O\ SBH^;5Z)6T\<]B%O?+CM0CB>K0   '?W=M_:&F^;
MK)?=/'1'W7E=Z7L_.[I3SBN6@                              (C.]0
M_83^\_\ AX)NS_5W?>@;[]/?]R(T3%>    E$[KS\_=T?BA3^[*A$W?ACM3M
MEXK=B:$05B                                @8[R3[0T+S=8U[IY$+
M':^5WJO>>=W0X!$A$    3<=V%]$NX'G%7\VJ(0-WXX[%ELO+GM26B*F@
M     "J1N!^?F;?&[)/=F:+BOACL4=_'/;+R(RT
M   67>4QIUGEOV>0\VXTL\-A.DEQ"D*-I]Z0^PX25$1FV\RXE:#\"DJ(RZ#(
M5>;S;=JZP>37L=$#DZ@        #$9#[ 7GM19>HGAF.+%N$]BIB+A0@
M"V=CWL!1^U%;ZB9%//%?5X1V,N,,@               *F%_[.W7MM9>K'A<
MQP4-N,]K$@P    M/[/?1'M;YN<(^;-8*B_CGME>8_+KV0V,-6X
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M\N.U".)ZM    =_=VW]H:;YNLE]T\=$?=>5WI>S\[NE/.*Y:
M                   B,[U#]A/[S_X>";L_U=WWH&^_3W_<B-$Q7@   )1.
MZ\_/W='XH4_NRH1-WX8[4[9>*W8FA$%8@
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M+_*+UKSY=KZ$V5XY::;G<Z3^J8F,&.>K2LVR6B>/-BM[$E ^T7QZ
M_BDI6E2%I)25$:5)41*2I*BT-*B/4C(R/I(!6FYJ=H%;*[T91B\:.IG'+%TL
MFQ!?5\#2L=N77G6(C.A$DTT\UM^"9_ZQQN+0M2%KAO[S'$^WVJ;/C]WDFOLX
MPYT'1Q    >HPG+[K ,NQS-<=?[-=8Q;PKBO6?%U:W8;R7%1I"4J2;L.8T2F
MGF]='&EJ2?09C%JQ:LUGA+:MII:+1QA:.P'-:7<;"\9SG'G>NI\HJ(EM$U4E
M3C':&_\ $09'#JE,ROE)6P\G_5=;47H"IM6:VFL\87=+1>L6CA+UXU;
M      C2[SWZ)=O_ #BH^;5Z)6T\<]B%O?+CM0CB>K0   '?W=M_:&F^;K)?
M=/'1'W7E=Z7L_.[I3SBN6@                              (C.]0_83
M^\_^'@F[/]7=]Z!OOT]_W(C1,5X   "43NO/S]W1^*%/[LJ$3=^&.U.V7BMV
M)H1!6(                               "!CO)/M#0O-UC7NGD0L=KY7
M>J]YYW=#@$2$0   !-QW87T2[@><5?S:HA W?CCL66R\N>U):(J:
M *I&X'Y^9M\;LD]V9HN*^&.Q1W\<]LO(C+0   !:(Y?_ *!MDO-%MM\S:45.
M3S+?ZI^U=XO*K_IC[&W1HZ                             #$9#[ 7GM
M19>HGAF.+%N$]BIB+A0@    "V=CWL!1^U%;ZB9%//%?5X1V,N,,@
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M-IU6HY,E9^E0(6ZQ],9([UCL\G1..>V/O2Q"&G           C2[SWZ)=O\
MSBH^;5Z)6T\<]B%O?+CM0CB>K0   '?W=M_:&F^;K)?=/'1'W7E=Z7L_.[I3
MSBN6@                              (C.]0_83^\_\ AX)NS_5W?>@;
M[]/?]R(T3%>    E$[KS\_=T?BA3^[*A$W?ACM3MEXK=B:$05B
M                      @8[R3[0T+S=8U[IY$+':^5WJO>>=W0X!$A$
M 3<=V%]$NX'G%7\VJ(0-WXX[%ELO+GM26B*F@        "J1N!^?F;?&[)/=
MF:+BOACL4=_'/;+R(RT    6B.7_ .@;9+S1;;?,VE%3D\RW^J?M7>+RJ_Z8
M^QMT:.@                             Q&0^P%Y[467J)X9CBQ;A/8J8
MBX4(     MG8][ 4?M16^HF13SQ7U>$=C+C#(               "IA?^SMU
M[;67JQX7,<%#;C/:Q(,    +3^SWT1[6^;G"/FS6"HOXY[97F/RZ]D-C#5N
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MODO_ "A]:_"?+=MZ&V5_][=3&?<:3TQBI;_:I/T7R1-Y]L>ZK[+)31]V/B0
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M\N.U".)ZM    =_=VW]H:;YNLE]T\=$?=>5WI>S\[NE/.*Y:
M                   B,[U#]A/[S_X>";L_U=WWH&^_3W_<B-$Q7@   )1.
MZ\_/W='XH4_NRH1-WX8[4[9>*W8FA$%8@
M    (&.\D^T-"\W6->Z>1"QVOE=ZKWGG=T. 1(1    $W'=A?1+N!YQ5_-JB
M$#=^..Q9;+RY[4EHBIH         JD;@?GYFWQNR3W9FBXKX8[%'?QSVR\B,
MM    %HCE_\ H&V2\T6VWS-I14Y/,M_JG[5WB\JO^F/L;=&CH
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MCK'&U[VBM:Q],S,0B[[>[;Y;LLWS#>WC'L\&*V2]IX5I2LVM:?HB(F5A#:W
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M#<;/[AI,566-,ENV5WAG7%7_ $PW2.;H
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M50\K3[B3/T!'W4:XN]*VDZ9NZ4_ KEJ
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M1&&0                           &(R'V O/:BR]1/#,<6+<)[%3$7"A
M    %L['O8"C]J*WU$R*>>*^KPCL9<89                5,+_ -G;KVVL
MO5CPN8X*&W&>UB08    6G]GOHCVM\W.$?-FL%1?QSVRO,?EU[(;&&K<
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M[OO0-]^GO^Y$:)BO    2B=UY^?NZ/Q0I_=E0B;OPQVIVR\5NQ-"(*Q
M    %8[?C?S-M]<RMKR^MIZ,=[?)][&*IDNHJ**I2ZI,!I$)"RC.V2HQ).3)
M-)N/.ZGJ2"0A-KCQUQUTCC[94N7+;+;69Z/9#18Z.0
M       ^F%"EV,R)7P([LN=/DL0H<5A!N/R9<IU#$>.RVGI6Z\\LDI(NDS,.
M'3/!GCT1Q6F-I,':VUVQP3 VR;->+XQ4U<UQG_92+1J*A=O,1_9-M7'G?_UB
MHO;GO-NN5WCKR4BO5#8@U;@        "#'O)]O7<>WBI<^88,J[<+'(Z),CA
MZ%9!BJ&*B6VI1%H6E&NN-.O2>BM.A(L-K;6G+[8E6;RFF2+^R8^Q'0)*&
M  /IBS9D):G(4N3$<6G@4N*^['6I&I*X%*:6A1IXB(]#Z-2!G68X/M\?WO\
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M&B8KP   $HG=>?G[NC\4*?W94(F[\,=J=LO%;L30B"L0        !4:%RH
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M#4>KKKDCA+1LQ8[;)S4Y9XQ]BKW>/EOSQX;?:C]$A$
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M5'%=N?-[EMM/)CMEW0(Z2        Q&0^P%Y[467J)X9CBQ;A/8J8BX4(
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MX]:SZ:UB+Z3CSZV4[#E-<1="TI>:/11="BT,N@Q;Q,3&L<)4DQ-9FL\888&
M   '5W)GO'Y'=[J"782"9Q;,3;PW*.L<)$>-$M94?Q=<.&M1--%36S;+KCAD
M:DQ#?2G[\QQSTY\<Z<8Z4C;Y/=Y(U\,]$K&XK%N        UGN_M7C6\^ 7N
MW^4-F4*V9)<*P:;0Y,I+>-JY6W, UFG23!?\*>))/-*6TL^!Q1'O2\X[<T-,
ME(R4FEN"M5NIM?ENSV:V^"YG 5#M:QPUQY*"6<"YJW''40;NH?6E':JRP0T9
MH5H2T*2IMQ*'4+0FTI>MZ\U>"FR4MCMRVXM=C9H
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M7'*BMD76]8A*GBGX=Q%ORWZ+*W/M9K^;'TUZNI&R)2$
M     "?WN[?LVUGQOROU5'%=N?-[EMM/)CMEW0(Z2        Q&0^P%Y[467
MJ)X9CBQ;A/8J8BX4(     MG8][ 4?M16^HF13SQ7U>$=C+C#(
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ME*B-QAPFY#/$7&A.I&=E3)7)&M53DQ7Q3I9I\;N8
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MW 7629;Q((W'G5+=<,M5*,^D1)M-IUM.LIU:UK&E8TAZ489
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MAXD9N%%C0V>+J8D=F,UQF2E]6PVEI'&HB(C5PH+4]"Z14+OAT/H
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M-?1F#TG;+6GSWY?.2/=S,1;)BMDMEKDI'ZHKS\E].FLUUM$1:LSQ0/F=]&@
M $1F9$1&9F>A$729F?@(B^Z$1,SI'%B9TZ9X.T>6SE8R;/,@J\KSFFETF 5D
MEJ<J/:QW(DW*W&%$ZQ API"$O^*'7"3VB0I*4.-:MM&I1FIOZ4_LO_8GYWZJ
M^;X/GWJC;9-KZ3P7B_+EK-+[J:]-:4I:.;W4SI[S),16U=:8YFTS:GSM_>#^
M]WR;TQ\JS_(_36XQ[GU3FI-.;%:+TVT6Z+7O>LZ>]B-?=XXF9K;2UXBL1%YC
M2(B(B(B(B+0B+H(B+P$1>@1#T9B(B-(X//J9F9UGB_H
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M= B04$A2S=4@DQFFBX5.'Q&7@-73X1B9F>+,1$<&4&&0
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M?G&@VSF4F-T]5*-M1*2I!R($-AXT&E1D9:Z:&83:T]$S,LQ6L=,1$2]:-6P
M         ,?95-5<Q^R7%97VL4EI<*-90HTZ/UB?O5]3*;=;XT^@>FI#,3,<
M&)B)XL!Y/L"^!&(?)JF]9#/-;KECEKU0>3[ O@1B'R:IO60<UNN3EKU0>3[
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MM9>@9&1C'-;KEGEKU0].,,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF2SUT9Y2>-M:%IUU29'H8FVP8HK,Q'3IURKZ;G--XB;=$S'LC\$_ KEJ
M (Z>?S??=;9/R3^3'*O>S[YO?WX[_P#0\<N>V^)O>;XM_."GM>S=F\:R/]CU
M?'UGI^+A3I*VV.F3FYXUTT^]$W67)CY>2=-=?N1T_P ]O-7]:?Z#[<?J@)/P
M^'J^N?Q0_BL_[OJC\#^>WFK^M/\ 0?;C]4 ^'P]7US^)\5G_ '?5'X'\]O-7
M]:?Z#[<?J@'P^'J^N?Q/BL_[OJC\&U]B^<GF1S+>3;+%,DW&\8T&0YK05-Q
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M'N!JV
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MRQQ]K>HYNH
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M+9BWIX([(4>3S+=LIY^1+[*FUG_OC_Y'R\5VX\Z>[[(6FU\BO?\ ;+KD<4@
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MG$DMMQMQ!FA;:T&1D9&9&1ZD.3L_0
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MM<66N6G-'%O,<W4
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MXUC73XCB7HLV#,91(BRH[J#-+C,AAQ*DJ+H,C%5,3$Z3Q7,3$QK'!]PPR
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MLT32""L0
M                       %:7FW^TEO!\;Y/J6(+7#Y5>Q3;CSK=J7+N[?L
MVUGQOROU5'$+<^;W+#:>3';+N@1TD      $&'>;?3SB7FBH?GEGPL-IY<_Z
MONA6;WS8_P!/WRV+W6WL_O'[489ZMR(:[OA7O;['C;LA,4(*P '+G.G]F#=K
MVIIOG50CM@\VKAN?)MV?>@"V?^EK:[SBX3\Y:P6-_!/9*JQ^97MA:@%0O
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MO!)L(B:
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M='][WO<[)XC\6<'^'\6]A_PG9N'P<'1KKKTZBLMKK/-XEO7ETCETY7HQAD
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M+L'9?\-V+LW#U75_@^KTX>C05DZZ]/%;1IIT<'V@R
3                      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>dnli-20210725_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20210725.xsd" xlink:type="simple"/>
    <context id="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2021-07-25</startDate>
            <endDate>2021-07-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl80L2ZyYWc6NmZkNzEwNGRmMzU5NGZiMThkOGZhMzNhMGUyOWQ5YjIvdGFibGU6YmM3YWFhZTVlNGM5NDNjNThiNjQyNzkyMWNlODM2MTcvdGFibGVyYW5nZTpiYzdhYWFlNWU0Yzk0M2M1OGI2NDI3OTIxY2U4MzYxN18yLTEtMS0xLTA_5acc48b8-2884-486b-9968-c96a21420638">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl80L2ZyYWc6NmZkNzEwNGRmMzU5NGZiMThkOGZhMzNhMGUyOWQ5YjIvdGFibGU6YmM3YWFhZTVlNGM5NDNjNThiNjQyNzkyMWNlODM2MTcvdGFibGVyYW5nZTpiYzdhYWFlNWU0Yzk0M2M1OGI2NDI3OTIxY2U4MzYxN18zLTEtMS0xLTA_ad1f0d96-c2b8-48bc-953e-f5fb9c3d968f">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDE4_fd429370-bf0c-427e-a6e9-b2e9764f4ec2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18yMzI_f545fb5f-baf0-4199-81af-0e017ec83dde">2021-07-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDE5_639a7e9a-403a-40e1-86e5-954ec7ab5827">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6YTc4NGY5ZjlkOWJmNDdmMDhmZjAzMjNkMTc1NjdkMDgvdGFibGVyYW5nZTphNzg0ZjlmOWQ5YmY0N2YwOGZmMDMyM2QxNzU2N2QwOF8wLTAtMS0xLTA_36b6e605-dc23-4c0a-a36a-8c8041550067">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6YTc4NGY5ZjlkOWJmNDdmMDhmZjAzMjNkMTc1NjdkMDgvdGFibGVyYW5nZTphNzg0ZjlmOWQ5YmY0N2YwOGZmMDMyM2QxNzU2N2QwOF8wLTItMS0xLTA_9ab34082-1b1e-4d04-af5d-934c920d19a7">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6YTc4NGY5ZjlkOWJmNDdmMDhmZjAzMjNkMTc1NjdkMDgvdGFibGVyYW5nZTphNzg0ZjlmOWQ5YmY0N2YwOGZmMDMyM2QxNzU2N2QwOF8wLTQtMS0xLTA_b0562af1-5cc1-4efe-97ef-e53d10ece82e">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIz_a1338a5b-908e-4eeb-a909-e8fcde5eb2c9">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIw_7142b4dc-99a3-4588-b5e1-b0544216ed9c">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDI1_8b084f9c-742f-4c2c-8fa1-b20dea0d410b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18zNzc_9d343123-2411-4e33-ac60-edf7edef127d">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIx_e1a74c17-27c2-40ae-938b-0bafaa97ab5b">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGV4dHJlZ2lvbjo2MGU5MTU4NWYzN2E0MTk5OTE1YTcwODFiYjg5MTBlY18xMDIy_ac939379-f2a5-481b-83e8-2625feb8cb12">866-8548</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8wLTAtMS0xLTA_6814c650-ef18-40ca-8e2b-937d9705c627">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8xLTAtMS0xLTA_c6182e60-4ba3-4959-98cc-7e7c3bf60943">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8yLTAtMS0xLTA_87b19725-b978-4764-bb66-32653d2ed511">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6MGM0NGRiY2VhOWNlNDEzM2E0YmMwODFmZGQ5MTY0YTUvdGFibGVyYW5nZTowYzQ0ZGJjZWE5Y2U0MTMzYTRiYzA4MWZkZDkxNjRhNV8zLTAtMS0xLTA_b4bb0f37-73fd-47f9-8c3c-492c5b40d5a7">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6NTc3MzNjNTg5ZmY3NDcwODg4NzA0NmRjNGEyMzE4OTgvdGFibGVyYW5nZTo1NzczM2M1ODlmZjc0NzA4ODg3MDQ2ZGM0YTIzMTg5OF8wLTEtMS0xLTA_4ac01fac-3ede-45b3-8078-b2ed99b9478c">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6ZWViODBhMWFiODFiNGQ2NWFmZWQwYzc3YmQ0ZTY3ZDcvdGFibGVyYW5nZTplZWI4MGExYWI4MWI0ZDY1YWZlZDBjNzdiZDRlNjdkN18xLTAtMS0xLTA_cace6d29-1aa1-4c3f-9f71-0073b23b46d9">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6ZWViODBhMWFiODFiNGQ2NWFmZWQwYzc3YmQ0ZTY3ZDcvdGFibGVyYW5nZTplZWI4MGExYWI4MWI0ZDY1YWZlZDBjNzdiZDRlNjdkN18xLTEtMS0xLTA_52c7c7c8-836a-4a59-8806-43526e3ef7ab">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i905d144ef3114ff28637a3f963092bb4_D20210725-20210725"
      id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTRmODU2OGRjNTQ3NzM4NTAyN2NhZDdkOGJhMTI2L3NlYzowN2U0Zjg1NjhkYzU0NzczODUwMjdjYWQ3ZDhiYTEyNl8xL2ZyYWc6NjBlOTE1ODVmMzdhNDE5OTkxNWE3MDgxYmI4OTEwZWMvdGFibGU6ZWViODBhMWFiODFiNGQ2NWFmZWQwYzc3YmQ0ZTY3ZDcvdGFibGVyYW5nZTplZWI4MGExYWI4MWI0ZDY1YWZlZDBjNzdiZDRlNjdkN18xLTItMS0xLTA_06d8b21f-f0c9-4e1c-8b6f-545883c0ded7">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140467478275256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 25,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V
M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N
M\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG
M5LJ]AU>RY1AQ_)[E#U!+ P04    " "]0_I2)!Z;HJT   #X 0  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K
M+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;
MM(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /
M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G
M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ O4/Z4F60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( +U#^E*#@5-5[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +U#^E*97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ O4/Z4@ .3:XX!   01   !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +U#^E*?H!OPL0(
M .(,   -              "  7P,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  - 3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20210725.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dnli-20210725.htm">dnli-20210725.htm</File>
    <File>dnli-20210725.xsd</File>
    <File>dnli-20210725_lab.xml</File>
    <File>dnli-20210725_pre.xml</File>
    <File>ex991pressrelease7262021.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dnli-20210725.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "dnli-20210725.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20210725_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20210725_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dnli-20210725.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20210725",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210725.htm",
      "contextRef": "i905d144ef3114ff28637a3f963092bb4_D20210725-20210725",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210725.htm",
      "contextRef": "i905d144ef3114ff28637a3f963092bb4_D20210725-20210725",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001714899-21-000066-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-21-000066-xbrl.zip
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M0BZ)D(G_1GX0<D41I* U,A9Y('NR&,1/MQ]F-&)Q/PU'**59D/HCT7+2('8
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M$@],8?Y0$.</*CJL0T.?1[1X1T(=3"KP6&N?1]-$=[2?=>($)N<]$M;:L(B
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MWJ1UPKZ,W9H%PST[?#_;12<X+/AJ\AM02P,$%     @ O4/Z4K;^8,E2"@
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M=;%U?N^ZF/0ADWEQG1?53E)UI>5I?I.5Q7UU6B6Z&>6A[D<#023 5+\(0@)
M. RPI#3DH>5U%CO'.S9I;A9,&IAKEP!OD%OJ=@CO0U><GHW-:5:>1A'IL PU
MB)X1RU&[_4^\+#4HV/;RU+##1MY^L?ESEF8*+83@$4QD#,* $8 QTDF%$@ZX
MH(&*H"_P\!ZZ=Y0C324/]Q%LWG@&K/<I<[WOHD'LT*PQDJYI<H4]4^XW7'0Q
M,?YNBX;7GW.K15=@O?=9=!J["O^+NDA79<&S\J/^K1>!GAS'A(= Q.;>"A4&
M@,62@)!%&(4B@L2VD6@.<*1R?P3I&92V(G]"XE!]NU,SC;2'LN(@Z.[01VCY
MB<.)9=P=3EO!/7;VXC6/E%E^OLRS[07#24C\(!$"<$Z0GH4GU-RL# %B?@01
M08+)P2O23YT?FV@K?%X%T/I*ZQ9Q^\4ZAHX#"]6""2N1]H7L)-"6L\G$V1=&
M79B]-B-;:3/[_U2<Y[?9@M!8!BP,013P"&"FA"ZJ"@,) T&QCR14;HWTXQC'
M)M&GS6&U?*1GD :K8PM=(]2R@7:C:>+V>1!#[JUSFX/QC7/-Y\]IF]M!]3;-
M':8.Z][Y#U6\%::"RW+(6F[=_HC.O0J7]]\MLO\]TW)N5[1NZ[D-3],MZ'8%
MT%C1[30862@^YZN2+_^37E<KBHQ @GQ(@ R" . (*ETUPAB$))18MW9$(,O+
M [N&.?9RL0;K:;1.B[:=S%H6#6>^)JX;0ZER+QV=3(RO'DVW/Z> =(;66T.Z
MK5WE?ZHRG4>6'[)8W?U;W2^H0%102@"+4 QP@!00D4A @B!-DH00%45VRG\R
MPI&*?H/2JV!Z&J>MVI\2.53H(^B91N/#F7$0=T_T(W3]U./$DNX)J*WF/D/W
MQU&\NY.7^O=3U>H?I%B1.$0 R4#KF 0<"(9\H%2H* P#14-I^TB*^@#')N,M
M1F\+TG()M9/$_1H>2\V!)6S)BM/#*;I"'_6 BH;#R1]2T15.UX,J.NWZQ%MG
M_$R_.WFQ_21=/TK[Y,7_ 5!+ P04    " "]0_I2&5 DT[$&  #P,   %0
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MMGB2(=9*K;P--% Q*NS?(@X+_82GF*,H?.'P?ZCSMH7RI%JOK\K[%JE9:NR
M+*78,V?&H!>:$L]4[%SAD6K.N1_WTW\2=I@0)CS#'$_F"ZOA?57D,6_S<O4[
M%CAU[HLE#5:$+..$<X&IC#,L;2#S1&CN.0T2FR,S2@J/,8?I8,(SRI$TOK (
MSFOH% Q8V/;[<]W6;OTV0SN6BEFL83PC B36N=H@(<)@*1-9,L"B#&'<ONSW
ML8>)8L)SRAW1.BUQG#;-%=1?^V*DS9)W@=C0W0"]=\1)KXD$2[$9$IDUXVX=
M_V;!,*%,>'"Y4XHGT6V^7D.]PFSX:UU=MY?HW,:7MY@2N8<4%=X7=4+CF<&^
M2'EB03*FF=".CMLR_P?P82*9_ !S/+$O77! O,*BZ9;Q<)&W!2Q99$$Q9($"
MQ](YX#OK;2(Q<DR$,:(SXV94WR(.4\*$IY:C*'SA\%_4OGO"\?WM.E18([$@
M'/Z1I&CL=,N)!^N(4,EHC*&Q;ESGN04W+/ 3GD@^G[R)_.A?W\1+7ZZ@?]3#
M@J(A=L^3@L<".7)!K ).A(4@K.? ];A-BZ=0AST_->&QXV@J)U$?G"!7M2].
ML<2Y^0WP!N:$DQGWQ"2@R(:TQ(K$B$\J>&-3D&X7&UC?P X3PX1'D./)?&$U
M'&.]F[J:]TWA5TO!DM4F921F@&5,S+)N;A*(UIYKYHV(<=R3,%MPPZ(_X2GD
M\\G;6=1?+1Z1=X8'CO;NO^A>ND?DC_;^!E!+ P04    " "]0_I23N'N@4<9
M  #H<   '    &5X.3DQ<')E<W-R96QE87-E-S(V,C R,2YH=&WM76MS&[>2
M_;Z_ E>NZTA5)$52#\N2XRJ9DFWMVHYBZ=JUGVZ!,R"):#B8G0<EYM?OZ08P
M,WQ:3B296^M4)98U Z#1W>@^_<#DU3_.?NM=__?EN1CEXTA<_NO-AXN>V&KN
M[G[=Z^WNGEV?B??7'S^(_5:[(ZY3&6<ZUR:6T>[N^:<ML37*\^1X=_?V]K9U
MN]<RZ7#W^O,N3;6_&QF3J5:8AUNO7]%O\%\EP]?_\>H?S:8X,T$Q5G$N@E3)
M7(6BR'0\%%]#E=V(9M.]U3/)--7#42ZZ[6Y'?#7IC9Y(^SS7>:1>^WE>[=J_
MO]KE15[U33A]_2K4$Z'#7[?TGGSY\FBOTSYL'_;WC]KM(WDT&!P<O S;+PZ"
MSI'Z=P=$[N)U.R;+IY'Z=6NLX^9(T?K'^]W6BX,D/[G583XZ[K3;_]R:>357
M=WE31GH8'S/!>#HPV)Y[')C(I,?/VOS/"3UI#N181]/C7TY3+:-?&AE8V\Q4
MJ@?V<:;_5%@'2_)?;RT9+S ZTK'R9'6Z1,CYW4CW-7A KS[,PMVYA?>7+BP>
M<LG[[?7ERU;'KVH%5HKM]:M<]B/EZ>B;-%1I$^1$,LG4L?_A)-19$LGIL8YY
M>AYT,I;I$.+NFSPWXV,2]42EN0YDY,3*$K:/*RUHM:TFY"G^#?W*[G&+'^WF
MX>*SO;W6T7YGY>-V:_6SM=-V6H?[1X\Q;;=S/VIWF1.I?\&)[F OH1.!@1!"
MELCXUZV]+?].(L,09_^X+3K\%DM2CX="1OFO6Z&"L='_SN\B,S1W[8YL_9$,
M,38-5C^;67M_/[G[2](]:B=WI57P&[\'_=_[*K-LE[5P1IFMCO?I85W=EQN=
M #90I0]D=>8/__*3>,;<%]<CE<I$%>!F)D[CV!1QH#)Q:<A33)2X(,+T6)S)
M7(I!:L;B<B0S)3K/G^V_..F*J[P(I^)6YR-Q?OWE^;.#HY.+LRNQ??;I PSV
MCM"QN)2YQOXR^U8^4N+#-#.9&<L(PTTJATJ<Z4S1M.\+6D]<3>,0:RFQ_?'R
M2EQ<["PP\3X,=O)J1FJ0'^\=@BW,<AU#\_+C9N<H>2Q#O]S>/G]VU.T>GCRF
MU5VV\,D,'SK[K0/:]V>9Z%"D*BP"@@1"QK +199+C Y%;%*(1_\I^9D9B)%*
M)/ #7HD&\/@DU][56Q&JL8FS/&40D)H^)N"9PB)E8][[="4D%ICHW&F)CO'V
M1$'1,B%#^&C-P[%,@T>J>"2A@J%(L->$M#.:FZ&D.2,JBA0$6^I56HP7")4#
M4J@,(X,1813686PS#F4:-LV@&<@4VP'!/")3/U7MH57M763ZD.+%.$E5ECF%
MZD',./@9C#CL34CF)2N&0Y61)@68F,R[T!AC)HJQ)H2-'Z$/D;!60633<0*3
MGS5@K8>Q-5BRKR/\I/#+OAK)B3:I5:QD-,UXSO*-GY)^:$F?WR584L*H3T5?
MP\*G-SA\+-Q92S%SA,F01*5+B#09IG)T!H\A851P2 .\#VM!NF!-B56.L#9X
M /=%\\(1O3QAL8] LIA([)?%/J4%U5(R/PV:'\2MS(3I@R4T+_2U:77'9'DS
MIUC'1BL_]>9A]>9*#A1$ W$.-+P&2[=(1&[$_IZX5>HF(Y,1&HXR243SJN -
M.KW&!EW%?TZ!'U*%6"&P]B-GJ%.ZH4%!IJB9JLBII'0:V5>T"N&4,<0.AZ'^
MI\#X:%HIA@QAB !7U(2 S4]]>&A]> ,_#%G&) 6PF0Q(0SC$JH$;@D!%BE #
M!*4& Y,"74)9-/D =OHBT1.3PR!8M-IEM+J'#1%:A07HO*><1/>GY!Y:<A]E
M##P_M@<3GGI$1TCB#/=U+%,!4<&@2AAL2(PLJXXG</D&9AY&OM/A &*O+61K
MW!+G$B<\C<6UQDG.32BGWR6OI\QK7/WVK^OWXNKTDWC[^?13[^*J]UM#]*"N
M@U9#_&<!V]$]:-@TV!HY=<.]P_W]!R>.%*33?7(%V7HME@69%W'0$MN?3J_.
M3G]G<0O$BA<[ &GDBY.11.01\+LXOH$9(PB? CU,5&02.N]X+362?'*:#TRD
M#=E\> Y"%+#]<:AA+@ I53P$00I0@TQ#D)HL8Z/>CXP)F_T4@8[HRS35</W;
M;]Z\V6'EC%6!J=10Q6Q? "A#&YH"3[(*0FMMD$Q>('3I5 ((%GYJ%R^'9;PL
MYR)F:X/41$:%-6#+XF:"K.YLZ*%TBS#-S02D 49!AFM\')$!>\1;9]PB^@9>
MC_(,%%!A<Q,*P#*<0S46VPC3=BS0J8*NL8SU .M+ZQ7!9!><9_/!>8L$7.X<
M&+^(<N]&"?)3<B/TW,L9O--):+ X.H</J)>'9(3N8;F,S8,?L_.'V$YRDQPW
M]UI+4DM]R(XFV'J=CW[ ">+\2^PUX H!#VA'F O?2'PDF7UV".:L5%0=!U$1
M(KBRL(IUT<*IKXRE *IH8/? :FC/C-B#GO)OWS1(A(FBF%M%TX8X; *Y0WGF
M 'UMJ!MIE]C[]NMO6MXR?,-=6)U9XS3Z"H<\9K. <0G,P)T>@QLPN&N<24ML
M@"-9X\S;)W2@(H, .6V"ZO&,)(D#*V0"K; &9$XZ@,LP-05YT7H@9M,T-BS"
M^0:2@M0M/J;$#>(K8.)&%6<M2\FLS:]X.&XC<.FWX7'^WT#Q#694YP13(EKL
MR=1@OO>F(3ZVSEH>*[+C>W&2B=Y(JX'XJ$)V*K\-!CI0:4LX9G]5'%[**#-8
M,3 %I201@DX=H(SP)XTL#6')D#)/X3,1O$\?A!+=X+^?RAMS!CMD:[$HI47A
MARBG,2#WD?A<J8JQHTB%'!\[,;9@#4JG0]834%A;IS;0*0Y.3D#IUNXF@R,E
M>2P>OH:X'>E@1$-#E<'&63>!B,A TQ!D83#@=5#+R=TKK*]T BQR:BBMWZ7]
M\<0ISBO$F+7$4HCO:)_!]Q#'7\#X%0DZKG%H)*,!/2/PSUO#C&Q#',-I0<>G
MGA^YS'UCV*!(21=K@E65/L#Y)@8>,6MY/<4_&VMTKEF3G/^VEE:SHJ_:OG,P
M86EUOJV\S.U.=^U+\ NGT)3RE9'$K(S(8H-?0FM]YL^!,FAFH)*</82)2PJL
M-8D1W:\=/+,P6=PQ# 1P%Q4D"%-Z,L"+0S%5,N6S:H&4=9F-JJ8Q!2BD[&4U
MC(W(@?6TU5HKW.S<SE,5*$T6AI(?T70F:TX'*:N?L646N);07H<3R6' PW:\
ML%F\+5OMF0=P#XDJ;'[.>['O 0]K)YPW5N5Y7)>"7H)FJFV)[OYWHH7Y J9K
M/5C$G*N:$5R9LUT-D?W,1$6^.&0E'?7_CM(J<S%4B'R4O&FRTAS+Z%9.LZT'
M;IM82<\3F[7/+A)Q3FA.?^ AS2VYOI$$QD$D&9E;G_BSAVGQ)$$I[*&SL4M$
M46FVHCP&A*$0J68(6BDQ'17 *=N]J[<[97'-VCY9/_=L?.G!=OS\V6'GI'.P
MXVQ,ZNIU60)_JZI4)&;@-&4YA1_9W2'8P3K\HN;RYS$7\X;]K+4 B(1IG+<M
M!-N\6R=_J+.L4*5O $IL"5M)7*@84E9_H1B7 ]7>SD(!7_:Q>7Y:OB2)"9R#
M<MS%1+!*?%'8$U#?]O67'4X*U^J/BB >\:,EWEH_/38$0XGHDG6A(ON@[E-%
M7)9S7@N++>G,Q-;&^OWS9::R7HJ[-]+E$.U>(%:0H.Z#BVL0\1X%Q.?/7G9.
M>DPDN?!U([9[[RZ:/9OON.2UUK]^R:]C@;T3?XX88+M@A<^QS."3,W:MCJ B
ML[!Z#*A14/&*9[,::%ELS<_3E#HW..*M*^%\%;#.J*IF6)?"]]4$CTX$C!ID
MVSFHV=SE[F$DO5$3[S[NB2'$%VEXY-#;?9]G893D)X/J+%HXFM &N+0$@9HB
M+>UD65:<"^]F:Z25J^GK;!L@R<A@&HEA-(6?,=%.,QG!U8S(5FV_^7BYXP+N
MQ!!K*(2M.CUF9AM&16"R:819(%+L;?M=%/14"HL*_S7C9JH3G/]%:/24:O6>
MZK[$=%#NPX*Y,G#%!0X3!CJ2?/JVJ1)L4[#+(U\_@AP[8E_PM2#G<I_:<:O6
M287Y33PT['QYF$_SQ1(3XD^$9;RR#;J@ZB1":S9=_LR=#2F8,L;HJ8]M8'GJ
M>[2.C8O<9%LP9K]UT"03Y6$X^3'#HIX'$WM0AY&!5P"9OABZU+BOCAFQ\2+U
M^,JO6++%K[UZ?&/Y?HC#A#1X7W5*'.4'.S4>F9!]FN-1F83LJTAC6M=I0.L7
M>9D4XXDA6%DCMD1AE4KHV%MJSF-2S5CC_"PF"2#A#3XU% 7/)>FJ0#-58]L=
M]C?R=BT_&1T66V6)H$RW"DS+#2=]5%A%U0QM S,>4Z+(\[^)&=,A33I;AW<1
MZYK2_O;%Y\_9#@PM_A F"(HTM0K<Z;)7>"&V7W3^N5/JOW493(C\PZ2D$N06
MP.ZPIF# /J1:G -SOSW<X36L.^Z4!H@&9R 6+*+'"/JQ:4IA8?$]TFAMV^)F
M=K5]=7J>.7OLD9/S961E)C0&+"Q!%5ZW>*Q<=NE1[7MT)>U^0%##)2MH00Y-
MULWPIIIA9DND0CP!3HF)8 KMK)PVJ7RN==V4E+8BJV<?*!-B^-A\6^3,%::_
M)H7-1=S7?I=E2MZVQ9HB)^KUP*69:_%HJDC_%0X8/^A/;6DP5(GBC@,+DG!
M-'P%#:#7=9XK1:+AVO-+6WK>7+:X1+S/V&:<](T457E3,P0R@0)2/RF[/GJV
MK(B[&!G"^N24U+8:6"6:9^HA$[@ JABS!OH19;A9 2B9<7HZG%![:KWV>_VE
MZ:ESU%*B^I;L(4UI ?YLO>+S%#+\*G/*(%Z.5E<LSN]44##6GZ]9_ 8F.':5
M++I3XR2""D&G9(*?@A)CSDT>&(I?.#XFC<,,\(DZH;"%,^P.0T3Z!IYQ9*Q?
MSHH@0(Q#$L@ESB(GY[E2;LB.8R>^XNZ\?%7R_U;]W<K'WB&J-_Y510E;_K<
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M=&U02P$"% ,4    " "]0_I29]J;)7$"  ",!P  $0              @ %
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9:'1M4$L%!@     %  4 3@$  ,I#      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
